# REGENXBIO Inc. (RGNX)

> Source: Nexqual · https://nexqual.com/RGNX · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, REGENXBIO Inc. (RGNX), nexqual.com/RGNX" · informational, not investment advice.

**Price:** USD 7.41 (+2.35% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 7.24 · day 7.21–7.63 · 52w 5.46–16.19 · market cap $489M · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $174M, net income -$196M (-112.6% margin), free cash flow -$250M (SEC filings).
- Analysts: Buy (mean 1.92 on a 1–5 scale) (12 analysts), mean target USD 23.58 (range 10–50).
- Total return with dividends: 1Y -43.5% vs S&P 500 +14.8%; 5Y -79.1% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05, EPS estimate USD -1.3, revenue estimate $15.7M. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
- Dividend: RGNX paid no cash dividend in the last five years.
- Short interest: 16.10% of float (as of 2026-10-15), 6.4 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $470M | $113M | $90.2M | $83.3M | $170M | $174M |
| Gross profit | $419M | $58.2M | $53.0M | $49.8M | — | — |
| Operating income | $160M | -$263M | -$268M | -$233M | -$161M | -$164M |
| Net income | $128M | -$280M | -$263M | -$227M | -$194M | -$196M |
| EPS (diluted) | $2.91 | -$6.50 | -$6.02 | -$4.59 | -$3.76 | — |
| Free cash flow | $135M | -$238M | -$228M | -$176M | -$126M | -$250M |
| Gross margin | 89.0% | 51.6% | 58.8% | 59.7% | — | — |
| Operating margin | 34.0% | -233.2% | -297.1% | -280.0% | -94.6% | -94.1% |
| Net margin | 27.2% | -248.7% | -292.0% | -272.5% | -113.8% | -112.6% |
| Revenue growth | +204.3% | -76.0% | -19.9% | -7.7% | +104.5% | — |
| Cash + short-term investments | $849M | $565M | $314M | $245M | $241M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 2.8x · P/B 6.8x · FCF yield -51.04% · Earnings yield -40.16%

## Analysts
Consensus Buy (mean 1.92 on a 1–5 scale), 12 analysts; mean target USD 23.58 (low 10, high 50).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-05 | Mizuho | Initiated | Outperform | $22 |
| 2026-08-25 | HC Wainwright & Co. | Target lowered | Buy | $23 → $21 |
| 2026-08-25 | Baird | Target lowered | Outperform | $32 → $29 |
| 2026-08-10 | HC Wainwright & Co. | Target lowered | Buy | $26 → $23 |
| 2026-08-07 | Barclays | Downgrade | Overweight → Equal-Weight | $12 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -43.5% | -79.1% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | -43.7% | -26.8% |
| Volatility (annualized) | 97.3% | 73.4% |
| Max drawdown | -64.6% (Jan 2026→May 2026) | -85.4% (Nov 2021→May 2026) |

## Dividends
RGNX paid no cash dividend in the last five years.

## Short interest
10,043,670 shares sold short, 16.10% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 7,927,603 shares (+26.7%). Days to cover: 6.4 (short shares ÷ average daily volume).

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 93.07 +1.20% · ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/RGNX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name RGNX in their own reports (relationship from RGNX's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Voyager Therapeutics, Inc. (VYGR) | 10-K 2026-03-09 | "For example, adverse events in gene therapy clinical trials, such as the more recent deaths in trials conducted by both Sarepta Therapeutics, Inc. and Capsida Biotherapeutics, Inc., respectively, and …" |
| partner | Ocugen, Inc. (OCGN) | 10-K 2026-03-04 | "We are aware of several companies focusing on gene therapies for various ophthalmic indications including Applied Genetic Technologies Corporation, as acquired by Beacon Therapeutics, Astellas Pharma …" |
| partner | uniQure N.V. (QURE) | 10-K 2026-03-02 | "In June 2020, uniQure France entered into an agreement, subsequently amended in June 2021, with Regenxbio for an exclusive (in the field of using AAV9 to expression of the GRIK2 gene in humans (the "F…" |
| partner | Ultragenyx Pharmaceutical Inc. (RARE) | 10-K 2026-02-18 | "Please see "—License and Collaboration Agreements—Clinical Product Candidates—REGENXBIO Inc." for a description of our license agreement with REGENXBIO Inc." |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-1.30 | $-0.97 | −$0.33 | $15.7M | 9 |
| Next quarter (ends 2026-12-31) | $-0.98 | $-0.68 | −$0.30 | $37.9M | 9 |
| Current fiscal year (ends 2026-12-31) | $-3.49 | $-2.79 | −$0.70 | $166.0M | 9 |
| Next fiscal year (ends 2027-12-31) | $-2.97 | $-2.54 | −$0.43 | $205.0M | 9 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-05): ±46.3%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 22 | 227.3% | ±46.3% |
| 2026-12-18 | 50 | 242.4% | ±68.0% |
| 2027-01-15 | 78 | 133.1% | ±59.9% |
| 2027-04-16 | 169 | 155.5% | ±79.3% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.43 | −$0.11 | Beat +$0.54 | — |
| — | Quarter ended Mar 31, 2026 | −$1.72 | −$1.41 | Miss −22.0% | — |
| — | Quarter ended Dec 31, 2025 | −$1.30 | −$0.84 | Miss −54.8% | — |
| — | Quarter ended Sep 30, 2025 | −$1.20 | −$1.30 | Beat +7.7% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).